-
1Academic Journal
Authors: V. A. Golovacheva, A. A. Golovacheva, A. R. Tarshilova, V. V. Osipova, В. А. Головачева, А. А. Головачева, А. Р. Таршилова, В. В. Осипова
Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 16, No 1S (2024): Спецвыпуск: Головная боль; 31-37 ; Неврология, нейропсихиатрия, психосоматика; Vol 16, No 1S (2024): Спецвыпуск: Головная боль; 31-37 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2024-1S
Subject Terms: междисциплинарный подход, medication overuse headache, treatment, ineffective therapy, preventive pharmacotherapy, migraine treatment, pharmacological methods, non-drug methods, interdisciplinary approach, лекарственно-индуцированная головная боль, лечение, неэффективная терапия, профилактическая фармакотерапия, купирование мигрени, лекарственные методы, нелекарственные методы
File Description: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/2379/1732; Kung D, Rodriguez G, Evans R. Chronic Migraine: Diagnosis and Management. Neurol Clin. 2023 Feb;41(1):141-59. doi:10.1016/j.ncl.2022.05.005. Epub 2022 Oct 31.; Филатова ЕГ, Осипова ВВ, Табеева ГР и др. Диагностика и лечение мигрени: рекомендации российских экспертов. Неврология, нейропсихиатрия, психосоматика. 2020;12(4):4-14. doi:10.14412/2074-2711-2020-4-4-14; Agostoni EC, Barbanti P, Calabresi P, et al; Italian Chronic Migraine Group. Current and emerging evidence-based treatment options in chronic migraine: a narrative review. J Headache Pain. 2019 Aug 30;20(1):92. doi:10.1186/s10194-019-1038-4; Мигрень. Клинические рекомендации МЗ РФ. 2021. ID: 295. Доступно по ссылке: https://cr.minzdrav.gov.ru/recomend/295_2; Hovaguimian A, Roth J. Management of chronic migraine. BMJ. 2022 Oct 10;379:e067670. doi:10.1136/bmj-2021-067670; Табеева ГР, Амелин АВ, Ахмадеева ЛР и др. Оптимизация купирования приступов мигрени. Неврология, нейропсихиатрия, психосоматика. 2023;15(2):126-33. doi:10.14412/2074-2711-2023-2-126-133; Табеева ГР. Проблемы выбора эффективного обезболивания при мигрени. Неврология, нейропсихиатрия, психосоматика. 2023;15(5):109-16. doi:10.14412/2074-2711-2023-5-109-116; Сергеев АВ, Табеева ГР, Филатова ЕГ и др. Применение новой биологической патогенетической терапии мигрени в клинической практике: консенсус экспертов Российского общества по изучению головной боли. Неврология, нейропсихиатрия, психосоматика. 2022;14(5):109-16. doi:10.14412/2074-2711-2022-5-109-116; Азимова ЮЭ, Амелин АВ, Алферова ВВ и др. Клинические рекомендации «Мигрень». Журнал неврологии и психиатрии им. С.С. Корсакова. 2022;122(1-3):4-36. doi:10.17116/jnevro20221220134; Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. doi:10.1177/0333102417738202; Modarresi S, Lukacs MJ, Ghodrati M, et al; CATWAD Consortium Group. A Systematic Review and Synthesis of Psychometric Properties of the Numeric Pain Rating Scale and the Visual Analog Scale for Use in People With Neck Pain. Clin J Pain. 2021 Oct 26;38(2):132-48. doi:10.1097/AJP.0000000000000999; Табеева ГР, Осипова ВВ, Филатова ЕГ и др. Диагностика и лечение лекарственно-индуцированной головной боли: рекомендации российских экспертов. Неврология, нейропсихиатрия, психосоматика. 2022;14(1):4- 13. doi:10.14412/2074-2711-2022-1-4-13; Osipova V, Ayzenberg I, Amelin A, et al. The highest prevalence of CDH in Russia: why? Cephalalgia. 2015;35(6S):287. doi:10.1177/0333102415581304; Головачева ВА, Парфенов ВА, Табеева ГР и др. Оптимизация ведения пациентов с хронической ежедневной головной болью. Журнал неврологии и психиатрии им. С.С. Корсакова. 2017;117(2):4-9. doi:10.17116/jnevro2017117214-9; Amin FM, Aristeidou S, Baraldi C, et al; European Headache Federation School of Advanced Studies (EHF-SAS). The association between migraine and physical exercise. J Headache Pain. 2018 Sep 10;19(1):83. doi:10.1186/s10194-018-0902-y; Burch RC, Buse DC, Lipton RB. Migraine: Epidemiology, Burden, and Comorbidity. Neurol Clin. 2019 Nov;37(4):631-49. doi:10.1016/j.ncl.2019.06.001. Epub 2019 Aug 27.; Ferracini GN, Florencio LL, Dach F, et al. Musculoskeletal disorders of the upper cervical spine in women with episodic or chronic migraine. Eur J Phys Rehabil Med. 2017 Jun;53(3):342-50. doi:10.23736/S1973-9087.17.04393-3. Epub 2017 Jan 24.; Al-Khazali HM, Younis S, Al-Sayegh Z, et al. Prevalence of neck pain in migraine: A systematic review and meta-analysis. Cephalalgia. 2022 Jun;42(7):663-73. doi:10.1177/03331024211068073. Epub 2022 Feb 15.; Harris P, Loveman E, Clegg A, et al. Systematic review of cognitive behavioural therapy for the management of headaches and migraines in adults. Br J Pain. 2015 Nov;9(4):213-24. doi:10.1177/2049463715578291; Probyn K, Bowers H, Mistry D, et al; CHESS team. Non-pharmacological self-management for people living with migraine or tension-type headache: a systematic review including analysis of intervention components. BMJ Open. 2017 Aug 11;7(8):e016670. doi:10.1136/bmjopen-2017-016670; Lee HJ, Lee JH, Cho EY, et al. Efficacy of psychological treatment for headache disorder: a systematic review and meta-analysis. J Headache Pain. 2019 Feb 14;20(1):17. doi:10.1186/s10194-019-0965-4; Sharpe L, Dudeney J, Williams ACC, et al. Psychological therapies for the prevention of migraine in adults. Cochrane Database Syst Rev. 2019 Jul 2;7(7):CD012295. doi:10.1002/14651858.CD012295.pub2; Bae JY, Sung HK, Kwon NY, et al. Cognitive Behavioral Therapy for Migraine Headache: A Systematic Review and MetaAnalysis. Medicina (Kaunas). 2021 Dec 28;58(1):44. doi:10.3390/medicina58010044; Sahai-Srivastava S, Sigman E, Uyeshiro Simon A, et al. Multidisciplinary Team Treatment Approaches to Chronic Daily Headaches. Headache. 2017 Oct;57(9):1482-91. doi:10.1111/head.13118. Epub 2017 Jul 25.; Cohen SP, Vase L, Hooten WM. Chronic pain: an update on burden, best practices, and new advances. Lancet. 2021 May 29;397(10289):2082- 97. doi:10.1016/S0140-6736(21)00393-7; Головачева ВА, Головачева АА, Парфенов ВА и др. Когнитивно-поведенческая терапия в лечении хронической мигрени: описание клинического случая. Неврология, нейропсихиатрия, психосоматика. 2021;13(1):74-80. doi:10.14412/2074-2711-2021-1-74-80; Головачева ВА, Головачева АА. Лечение хронической мигрени и боли в шее с помощью когнитивно-поведенческой терапии. Клинический случай. Consilium Medicum. 2021;23(11):852-7. doi:10.26442/20751753.2021.11.201137; Головачева ВА, Головачева АА, Парфенов ВА. Терапия при хронической мигрени: междисциплинарный подход. Клиническое наблюдение. Терапевтический архив. 2021;93(12):1528-32. doi:10.26442/00403660.2021.12.201247; Головачева ВА, Головачева АА, Володарская ЕА, Бахтадзе МА. Клинико-психологические характеристики пациентов с мигренью. Медицинский Совет. 2022;(21):78-87. doi:10.21518/2079-701X-2022-16-21-78-87; Головачева ВА, Головачева АА, Фатеева ТГ, Володарская ЕА. «Внутренняя картина болезни» у пациентов с хронической мигренью: когнитивные, эмоциональные и поведенческие аспекты. Неврология, нейропсихиатрия, психосоматика. 2023;15(1):28-35. doi:10.14412/2074-2711-2023-1-28-35; Головачева ВА. Лечение хронической мигрени и инсомнии с помощью когнитивно-поведенческой терапии. Медицинский Совет. 2023;(3):68-76. doi:10.21518/ms2023-080; Головачева ВА. Междисциплинарное лечение, включающее когнитивно-поведенческую терапию и майндфулнесс, при хронической мигрени и лекарственно-индуцированной головной боли. Медицинский Совет. 2023;(10):80-8. doi:10.21518/ms2023-216; Лебедева ЕР, Кобзева НР, Гилев ДВ, Олесен Е. Анализ качества диагностики и лечения первичной головной боли в разных социальных группах Уральского региона. Неврология, нейропсихиатрия, психосоматика. 2015;7(1):19-26. doi:10.14412/2074-2711-2015-1-19-26; Азимова ЮЭ, Сергеев АВ, Осипова ВВ, Табеева ГР. Диагностика и лечение головных болей в России: результаты анкетного опроса врачей. Российский журнал боли. 2010;(3,4):12-7. Доступно по ссылке: https://elibrary.ru/item.asp?id=23885076; Evers S, Jensen R; European Federation of Neurological Societies. Treatment of medication overuse headache – guideline of the EFNS headache panel. Eur J Neurol. 2011 Sep;18(9):1115-21. doi:10.1111/j.1468-1331.2011.03497.x; Chen PK, Wang SJ. Medication Overuse and Medication Overuse Headache: Risk Factors, Comorbidities, Associated Burdens and Nonpharmacologic and Pharmacologic Treatment Approaches. Curr Pain Headache Rep. 2019 Jul 26;23(8):60. doi:10.1007/s11916-019-0796-7; Амелин АВ, Богданова ЮН, Корешкина МИ и др. Диагностика первичных и симптоматических форм хронической ежедневной головной боли. Журнал неврологии и нейропсихиатрии им. С.С. Корсакова. 2011;111(1):86-8. Доступно по ссылке: https://elibrary.ru/item.asp?id=16597341; Осипова ВВ, Азимова ЮЭ, Табеева ГР и др. Диагностика головных болей в России и странах постсоветского пространства: состояние проблемы и пути ее решения. Анналы клинической и экспериментальной неврологии. 2012;6(2):16-21. Доступно по ссылке: https://annaly-nevrologii.com/journal/pathID/article/view/275/171/ru_RU; Becker WJ. Acute Migraine Treatment in Adults. Headache. 2015 Jun;55(6):778-93. doi:10.1111/head.12550. Epub 2015 Apr 15.; Steiner TJ, Paemeleire K, Jensen R, et al; European Headache Federation; Lifting The Burden: The Global Campaign to Reduce the Burden of Headache Worldwide; World Health Organization. European principles of management of common headache disorders in primary care. J Headache Pain. 2007 Oct;8 Suppl 1:S3-47. doi:10.1007/s10194-007-0366-y; Buse DC, Greisman JD, Baigi K, Lipton RB. Migraine Progression: A Systematic Review. Headache. 2019 Mar;59(3):306-38. doi:10.1111/head.13459. Epub 2018 Dec 27.; Torres-Ferrus M, Ursitti F, Alpuente A, et al; School of Advanced Studies of European Headache Federation (EHF-SAS). From transformation to chronification of migraine: pathophysiological and clinical aspects. J Headache Pain. 2020 Apr 29;21(1):42. doi:10.1186/s10194-020-01111-8
-
2Academic Journal
Authors: Y. V. Zhitkova, A. A. Gasparian, A. F. Sarvarova, D. A. Korobova, F. I. Galyavova, A. I. Baynazarova, A. M. Khamidullina, E. V. Domanskaya, Ю. В. Житкова, Г. А. Гаспарян, А. Ф. Сарварова, Д. А. Коробова, Ф. И. Галявова, А. И. Байназарова, А. М. Хамидуллина, Е. В. Доманская
Source: Meditsinskiy sovet = Medical Council; № 3 (2024); 43-50 ; Медицинский Совет; № 3 (2024); 43-50 ; 2658-5790 ; 2079-701X
Subject Terms: поддержание самообслуживания пациента с деменцией, cognitive impairment, Alzheimer’s disease, cognitive stimulation therapy, non-drug treatments for dementia, cognitive training, supporting self-care of a patient with dementia, деменция, болезнь Альцгеймера, когнитивная стимулирующая терапия, нелекарственные методы лечения деменции, когнитивный тренинг
File Description: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/8182/7210; Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D et al. Dementia prevention, intervention, and care. Lancet. 2017;390(10113): 2673–734. https://doi.org/10.1016/S0140-6736(17)31363-6.; Парфенов ВА, Захаров ВВ, Преображенская ИС. Когнитивные расстройства. М.; 2014. 192 с.; Парфенов ВА. Болезнь Альцгеймера: ошибки ведения пациентов. Медицинский совет. 2020;(19):23–28. https://doi.org/10.21518/2079-701X-2020-19-23-28.; Локшина АБ, Гришина ДА. Терапия некогнитивных нервно-психических расстройств при болезни Альцгеймера. Неврология, нейропсихиатрия, психосоматика. 2021;13(6):132–138. https://doi.org/10.14412/2074-2711-2021-6-132-138.; Kontis V, Bennett JE, Mathers CD, Li G, Foreman K, Ezzati M. Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble. Lancet. 2017;389(10076):1323–1335. https://doi.org/10.1016/S0140-6736(16)3238.; Михайлова НМ. Деменции позднего возраста: смертность и сроки дожития. Психиатрия. 2019;17(2):54–67. https://doi.org/10.30629/2618-6667-2019-17-2-54-67.; Helmer C, Joly P, Letenneur L, Commenges D, Dartigues JF. Mortality with Dementia: Results from a French Prospective Community-based Cohort. Am J Epidemiol. 2001;154(7):642–648. https://doi.org/10.1093/aje/154.7.642.; Rait G, Walters K, Bottomley C, Petersen I, Iliffe S, Nazareth I. Survival of people with clinical diagnosis of dementia in primary care: cohort study. BMJ. 2010;341:c3584. https://doi.org/10.1136/bmj.c3584.; Villarejo A, Benito-León J, Trincado R, Posada IJ, Puertas-Martín V, Boix R et al. Dementia-associated mortality at thirteen years in the NEDICES Cohort Study. J Alzheimers Dis. 2011;26(3):543–551. https://doi.org/10.3233/JAD-2011-110443.; Gillum RF, Yorrick R, Obisesan ThO. Population Surveillance of Dementia Mortality Int. J Environ Res Public Health. 2011;8(4):1244–1257. https://doi.org/10.3390/ijerph8041244.; Хасанова ДР, Житкова ЮВ, Яушева ЛМ. Лекарственная терапия и когнитивное стимулирование у больных с постинсультными когнитивными нарушениями. Неврология, нейропсихиатрия, психосоматика. 2014;(2S):22–27. https://doi.org/10.14412/2074-2711-2014-2S-22-27.; Spector A, Orrell M, Davies S, Woods B. Can reality orientation be rehabilitated? Development and piloting of an evidence based programme of cognition-based therapies for people with dementia. Neuropsychol Rehabil. 2001;11(3–4):377–397. https://doi.org/10.1080/09602010143000068.; Spector A, Thorgrimsen L, Woods B, Royan L, Davies S, Butterworth M, Orrell M. Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: Randomised Controlled Trial. Br J Psychiatry. 2003;183:248–254. https://doi.org/10.1192/bjp.183.3.248.; Spector A, Gardner C, Orrell M. The impact of Cognitive Stimulation Therapy groups on people with dementia: views from participants, their carers and group facilitators. Aging Ment Health. 2011;15(8):945–949. https://doi.org/10.1080/13607863.2011.586622.; Orrell M, Spector A, Thorgrimsen L, Woods B. A pilot study examining the effectiveness of maintenance Cognitive Stimulation Therapy (MCST) for people with dementia. Int J Geriatr Psychiatry. 2005;20(5):446–451. https://doi.org/10.1002/gps.1304.; Knapp M, Thorgrimsen L, Patel A, Spector A, Hallam A, Woods B, Orrell M. Cognitive Stimulation Therapy for people with dementia: cost effectiveness analysis. Br J Psychiatry. 2006;188:574–580. https://doi.org/10.1192/bjp.bp.105.010561.; Aguirre E, Hoare Z, Streater A, Spector A, Woods B, Hoe J, Orrell M. Cognitive stimulation therapy (CST) for people with dementia – who benefits most? Int J Geriatr Psychiatry. 2013;28(3):284–290. https://doi.org/10.1002/gps.3823.; Lobbia A, Carbone E, Faggian S, Gardini S, Piras F, Spector A, Borella E. The efficacy of cognitive stimulation therapy (CST) for people with mild-to-moderate dementia. Eur Psychol. 2018;24(3). https://doi.org/10.1027/1016-9040/a000342.; Niu YX, Tan JP, Guan JQ, Zhang ZQ, Wang LN. Cognitive stimulation therapy in the treatment of neuropsychiatric symptoms in Alzheimer’s disease: a randomized controlled trial. Clin Rehabil. 2010;24(12):1102–1111. https://doi.org/10.1177/0269215510376004.; Apóstolo JLA, Cardoso DFB, Rosa AI, Paúl C. The effect of cognitive stimulation on nursing home elders: A randomized controlled trial. J Nurs Scholarsh. 2014;46(3):157–166. https://doi.org/10.1111/jnu.12072.; Orgeta V, Leung P, Yates L, Kang S, Hoare Z, Henderson C et al. Individual cognitive stimulation therapy for dementia: a clinical effectiveness and cost-effectiveness pragmatic, multicentre, randomised controlled trial. Health Technol Assess. 2015;19(64):1–108. https://doi.org/10.3310/hta19640.; Stott J, Spector A. A review of the effectiveness of memory interventions in mild cognitive impairment (MCI). Int Psychogeriatr. 2011;23(4):526–538. https://doi.org/10.1017/S1041610210001973.; Bahar-Fuchs A, Clare L, Woods B. Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer’s disease and vascular dementia (Review). Alzheimers Res Ther. 2013;5(4):35. https://doi.org/10.1186/alzrt189.; Piras F, Carbone E, Faggian S, Salvalaio E, Gardini S, Borella E. Efficacy of cognitive stimulation therapy for older adults with vascular dementia. Dement Neuropsychol. 2017;11(4):434–441. https://doi.org/10.1590/1980-57642016dn11-040014.; Clare L, Woods RT. Cognitive training and cognitive rehabilitation for people with early-stage Alzheimer’s disease: A review. Neuropsychol Rehabil. 2004;14(4):385–401. https://doi.org/10.1080/09602010443000074.; Gibbor L, Yates L, Volkmer A, Spector A. Cognitive stimulation therapy (CST) for dementia: a systematic review of qualitative research. Aging Mental Health. 2021;25(6):980–990. https://doi.org/10.1080/13607863.2020.1746741.; Cao Y, Wang N, Zhang Q, Shen N, Bai J, Luo X, Liu Y. Effects of cognitive stimulation therapy on patients with dementia: An umbrella review of systematic reviews and meta-analyses. Exp Gerontol. 2023;177:112197. https://doi.org/10.1016/j.exger.2023.112197.; Aguirre E, Spector A, Hoe J, Russell IT, Knapp M, Woods RT, Orrell M. Maintenance Cognitive Stimulation Therapy (CST) for dementia: a single-blind, multi-centre, randomized controlled trial of Maintenance CST vs. CST for dementia. Trials. 2010;11:46. https://doi.org/10.1186/1745-6215-11-46.; Fairbairn А, Gould N, Kendall Т, Ashley Р, Bainbridge I, Bower L et al. Dementia: A NICE-SCIE Guideline on Supporting People with Dementia and Their Carers in Health and Social Care. Leicester (UK): British Psychological Society; 2007.; Рощина ИФ, Калантарова МВ, Шведовская АА, Хромов АИ. Профилактика когнитивного снижения в позднем онтогенезе: программы «Клиника памяти» и «Когнитивная стимулирующая терапия». Клиническая и специальная психология. 2022;11(3):44–70. https://doi.org/10.17759/cpse.2022110302.
-
3Academic Journal
Authors: G. R. Tabeeva, V. V. Osipova, E. G. Filatova, Yu. E. Azimova, A. V. Amelin, A. R. Artyomenko, Yu. D. Vorobyeva, E. V. Ekusheva, M. I. Koreshkina, E. R. Lebedeva, N. V. Latysheva, M. V. Naprienko, A. V. Sergeev, K. V. Skorobogatykh, V. A. Golovacheva, A. P. Rachin, V. A. Parfenov, Г. Р. Табеева, В. В. Осипова, Е. Г. Филатова, Ю. Э. Азимова, А. В. Амелин, А. Р. Артеменко, Ю. Д. Воробьева, Е. В. Екушева, М. И. Корешкина, Е. Р. Лебедева, Н. В. Латышева, М. В. Наприенко, А. В. Сергеев, К. В. Скоробогатых, В. А. Головачева, А. П. Рачин, В. А. Парфенов
Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 14, No 1 (2022); 4-13 ; Неврология, нейропсихиатрия, психосоматика; Vol 14, No 1 (2022); 4-13 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2022-1
Subject Terms: нелекарственные методы, evaluation, classification, chronic migraine, chronic tension-type headache, medication-overuse headache treatment, prevention, non-pharmacological methods, диагностика, классификация, хроническая мигрень, хроническая головная боль напряжения, лечение лекарственно-индуцированной головной боли, профилактика
File Description: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/1741/1362; Diener HC, Holle D, Solbach K, Gaul C. Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol. 2016 Oct;12(10):575-83. doi:10.1038/nrneurol.2016.124. Epub 2016 Sep 12.; Evers S, Marziniak M. Clinical features, pathophysiology, and treatment of medicationoveruse headache. Lancet Neurol. 2010 Apr;9(4):391-401. doi:10.1016/S1474-4422(10)70008-9; Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders ICHD-3, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. doi:10.1177/0333102417738202; Westergaard ML, Hansen EH, Glümer C, et al. Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. Cephalalgia. 2014;34(6):409-25. doi:10.1177/0333102413512033; Aaseth K, Grande RB, Kvaerner KJ, et al. Prevalence of secondary chronic headaches in a population-based sample of 30–44-yearold persons. The Akershus study of chronic headache. Cephalalgia. 2008 Jul;28(7):705-13. doi:10.1111/j.1468-2982.2008.01577.x. Epub 2008 May 21.; Jonsson P, Hedenrud T, Linde M. Epidemiology of medication overuse headache in the general Swedish population. Cephalalgia. 2011 Jul;31(9):1015-22. doi:10.1177/0333102411410082. Epub 2011 May 31.; Straube A, Pfaffenrath V, Ladwig KH, et al. Prevalence of chronic migraine and medication overuse headache in Germany – the German DMKG headache study. Cephalalgia. 2010 Feb;30(2):207-13. doi:10.1111/j.1468-2982.2009.01906.x; Ayzenberg I, Katsarava Z, Sborowski A, et al; Lifting the Burden. The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia. 2012 Apr;32(5):373-81. doi:10.1177/0333102412438977; Vandenbussche N, Laterza D, Lisicki M, et al. Medication-overuse headache: a widely recognized entity amidst ongoing debate. J Headache Pain. 2018 Jul 13;19(1):50. doi:10.1186/s10194-018-0875-x; Dyb G, Holmen T, Zwart J. Analgesic overuse among adolescents with headache: The HeadHunt-Youth Study. Neurology. 2006 Jan 24;66(2):198-201. doi:10.1212/01.wnl.0000193630.03650.19; Lipton RB, Manack A, Ricci JA, et al. Prevalence and burden of chronic migraine in adolescents: results of the chronic daily headache in adolescents study (C-dAS). Headache. 2011 May;51(5):693-706. doi:10.1111/j.1526-4610.2011.01885.x; Wiendels NJ, van der Geest MC, Neven AK, et al. Chronic daily headache in children and adolescents. Headache. 2005 Jun;45(6):678-83. doi:10.1111/j.1526-4610.2005.05137.x; De Rijk P, Resseguier N, Donnet A. Headache characteristics and clinical features of elderly migraine patients. Headache. 2018 Apr;58(4):525-33. doi:10.1111/head.13247. Epub 2017 Dec 13.; Diener HC, Limmroth V. Medication-overused headache: a worldwide problem. Lancet Neurol. 2004 Aug;3(8):475-83. doi:10.1016/S1474-4422(04)00824-5; Colas R, Munoz P, Temprano R, et al. Chronic daily headache with analgesic overuse: epidemiology and impact on quality of life. Neurology. 2004 Apr 27;62(8):1338-42. doi:10.1212/01.wnl.0000120545.45443.93; Meskunas CA, Tepper SJ, Rapoport AM, et al. Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache. 2006 May;46(5):766-72. doi:10.1111/j.1526-4610.2006.00442.x; Find NL, Terlizzi R, Munksgaard SB, et al; COMOESTAS Consortium. Medication overuse headache in Europe and Latin America: general demographic and clinical characteristics, referral pathways and national distribution of painkillers in a descriptive, multinational, multicenter study. J Headache Pain. 2015;17:20. doi:10.1186/s10194-016-0612-2. Epub 2016 Mar 8.; Paemeleire K, Bahra A, Evers S, et al. Medication-overuse headache in patients with cluster headache. Neurology. 2006;67(1):109-13 doi:10.1007/s11916-008-0023-4; Robbins MS, Grosberg BM, Napchan U, et al. Clinical and prognostic subforms of new daily-persistent headache. Neurology. 2010 Apr 27;74(17):1358-64. doi:10.1212/WNL.0b013e3181dad5de; Baandrup L, Jensen R. Chronic post-traumatic headache – a clinical analysis in relation to the International Headache Classification. Cephalalgia. 2005 Feb;25(2):132-8. doi:10.1111/j.1468-2982.2004.00818.x; Russell MB, Lundqvist C. Prevention and management of medication overuse headache. Curr Opin Neurol. 2012 Jun;25(3):290-5. doi:10.1097/WCO.0b013e328352c431; Linde M, Gustavsson A, Stovner LJ, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012 May;19(5):703-11. doi:10.1111/j.1468-1331.2011.03612.x. Epub 2011 Dec 5.; Bendtsen L, Munksgaard S, Tassorelli C, et al; COMOESTAS Consortium. Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project). Cephalalgia. 2014 May;34(6):426-33. doi:10.1177/0333102413515338. Epub 2013 Dec 9.; Schwedt TJ, Hentz JG, Sahai-Srivastava S, et al; MOTS Investigators. Headache characteristics and burden from chronic migraine with medication overuse headache: Cross-sectional observations from the Medication Overuse Treatment Strategy trial. Headache. 2021 Feb;61(2):351-62. doi:10.1111/head.14056. Epub 2021 Jan 12.; Schwedt TJ, Buse DC, Argoff CE, et al. Medication Overuse and Headache Burden Results From the CaMEO Study. Neurol Clin Pract. 2021 Jun;11(3):216-26. doi:10.1212/CPJ.0000000000001037; Tassorelli C, Jensen R, Allena M, et al. The added value of an electronic monitoring and alerting system in the management of medication-overuse headache: A controlled multicentre study. Cephalalgia. 2017 Oct;37(12):1115-25. doi:10.1177/0333102416660549. Epub 2016 Jul 20.; Katsarava Z, Jensen R. Medication-overuse headache: where are we now? Curr Opin Neurol. 2007 Jun;20(3):326-30. doi:10.1097/WCO.0b013e328136c21c; Diener HC, Antonaci F, Braschinsky M, et al. European Academy of Neurology guideline on the management of medication-overuse headache. Eur J Neurol. 2020 Jul;27(7):1102- 16. doi:10.1111/ene.14268. Epub 2020 May 19.; Сергеев АВ, Мещерина МИ, Табеева ГР. Головная боль, связанная с избыточным приемом анальгетиков: клинико-психологический и нейрофизиологический анализ, особенности периода отмены. Эпилепсия и пароксизмальные состояния. 2011;3(3):21-8.; Истомина ОИ, Филатова ЕГ. Абузусная головная боль: социально-демографический и клинический анализ. Врач. 2011;(1):68-71.; Tassorelli C, Jensen R, Allena M, et al. A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study. Cephalalgia. 2014 Aug;34(9):645-55. doi:10.1177/0333102414521508. Epub 2014 Feb 20.; Kristoffersen ES, Lundqvist C. Medicationoveruse headache: epidemiology, diagnosis and treatment. Ther Adv Drug Saf. 2014 Apr;5(2):87-99. doi:10.1177/2042098614522683; Osipova V, Jensen R, Tassorelli C. The use of diaries in the management of headache. In: Martelletti P, Steiner TJ, editors. Handbook of Headache (Practical Management). 2011. Vol. 4. P. 197-209. doi:10.1007/978-88-470-1700-9_13; Mitsikostas DD, Ashina M, Craven A, et al & EHF Committee. European Headache Federation consensus on technical investigation for primary headache disorders. J Headache Pain. 2015;17:5. doi:10.1186/s10194-016-0596- y. Epub 2016 Feb 9.; Practice parameter: the utility of neuroimaging in the evaluation of headache in patients with normal neurologic examinations (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 1994 Jul;44(7):1353-4. doi:10.1212/wnl.44.7.1353; Осипова ВВ, Скоробогатых КВ, Артеменко АР, Сергеев АВ. Тяжелая лекарственно-индуцированная головная боль с возможными повторными ее статусами у пациента с хронической головной болью напряжения. Неврология, нейропсихиатрия, психосоматика. 2020;12(4):73-8. doi:10.14412/2074-2711-2020-4-73-78.; Филатова ЕГ, Осипова ВВ, Табеева ГР и др. Диагностика и лечение мигрени: рекомендации российских экспертов. Неврология, нейропсихиатрия, психосоматика. 2020;12(4):4-14. doi:10.14412/2074-2711- 2020-4-4-14.; Schwedt TJ, Alam A, Reed ML, et al. Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. J Headache Pain. 2018 May 24;19(1):38. doi:10.1186/s10194-018-0865-z; Cevoli S, Sancisi E, Grimaldi D, et al. Family history for chronic headache and drug overuse as a risk factor for headache chronification. Headache. 2009 Mar;49(3):412-8. doi:10.1111/j.1526-4610.2008.01257.x; Bigal ME, Rapoport AM, Sheftell FD, et al. Transformed migraine and medication overuse in a tertiary headache centre-clinical characteristics and treatment outcomes. Cephalalgia. 2004 Jun;24(6):483-90. doi:10.1111/j.1468-2982.2004.00691.x; Meng ID, Dodick D, Ossipov MH, Porreca F. Pathophysiology of medication overuse headache: insights and hypotheses from preclinical studies. Cephalalgia. 2011 May;31(7):851-60. doi:10.1177/0333102411402367. Epub 2011 Mar 28.; Calabresi P, Cupini L. Medication-overuse headache: similarities with drug addiction. Trends Pharmacol Sci. 2005 Feb;26(2):62-8. doi:10.1016/j.tips.2004.12.008; Srikiatkhachorn A, Anthony M. Serotonin receptor adaptation in patients with analgesicinduced headache. Cephalalgia. 1996 Oct;16(6):419-22. doi:10.1046/j.1468-2982.1996.1606419.x; Kondratieva N, Azimova J, Skorobogatykh K, et al. Biomarkers of migraine: Part 1 – Genetic markers. J Neurol Sci. 2016 Oct 15;369:63-76. doi:10.1016/j.jns.2016.08.008. Epub 2016 Aug 3.; Bongsebandhu-Phubhakdi S, Srikiatkhachorn A. Pathophysiology of medication-overuse headache: implications from animal studies. Curr Pain Headache Rep. 2012 Feb;16(1):110-5. doi:10.1007/s11916-011- 0234-y; Munksgaard S, Ertsey C, Frandsen E, et al. Circulating nociceptin and CGRP in medication-overuse headache. Acta Neurol Scand. 2019 Mar;139(3):269-75. doi:10.1111/ane.13053. Epub 2018 Dec 11.; Riederer F, Schaer M, Gantenbein AR, et al. Cortical Alterations in MedicationOveruse Headache. Headache. 2017 Feb;57(2):255-65. doi:10.1111/head.12993. Epub 2016 Dec 28.; Diener HC, Dodick D, Evers S, et al. Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol. 2019 Sep;18(9):891-902. doi:10.1016/S1474-4422(19)30146-2. Epub 2019 Jun 4.; Carlsen LN, Westergaard ML, Bisgaard M, et al. National awareness campaign to prevent medication-overuse headache in Denmark. Cephalalgia. 2018 Jun;38(7):1316-25. doi:10.1177/0333102417736898. Epub 2017 Oct 10.; Шагбазян АЭ, Ковальчук НА, Табеева ГР. Роль образовательных программ в ведении пациентов с медикаментозно-индуцированной головной болью. Неврология, нейропсихиатрия, психосоматика. 2021;13(3):27-33. doi:10.14412/2074-2711-2021-3-27-33.; Данилов АБ, Шевченко ЕВ. Влияние информационно-образовательной подготовки пациента на клинические, финансово-экономические факторы и удовлетворенность лечением. Неврология, нейропсихиатрия, психосоматика. 2014;(2):29-33. doi:10.14412/2074-2711-2014-2-29-33.; Kristoffersen ES, Straand J, Russell MB, Lundqvist C. Lasting improvement of medication-overuse headache after brief intervention – a long-term follow-up in primary care. Eur J Neurol. 2017 Jul;24(7):883-91. doi:10.1111/ene.13318. Epub 2017 May 23.; Zeeberg P, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia. 2006 Oct;26(10):1192-8. doi:10.1111/j.1468-2982.2006.01190.x; Carlsen LN, Munksgaard SB, Jensen RH, Bendtsen L. Complete detoxification is the most effective treatment of medication-overuse headache: a randomized controlled open-label trial. Cephalalgia 2018;38:225-36. doi:10.1177/0333102417737779; Tepper SJ, Diener HC, Ashina M, et al. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. Neurology. 2019 May 14;92(20):e2309- e2320. doi:10.1212/WNL.0000000000007497; De Goffau MJ, Klaver ARE, Willemsen MG, et al. The Effectiveness of Treatments for Patients with Medication Overuse Headache: A Systematic Review and Meta-Analysis. J Pain. 2017 Jun;18(6):615- 27. doi:10.1016/j.jpain.2016.12.005; Сергеев АВ, Парфенов ВА. Лекарственно-индуцированная головная боль. Практические рекомендации. Медицинский совет. 2018;(1):26-32. doi:10.21518/2079-701X2018-1-26-32.; Chiang CC, Schwedt TJ, Wang SJ, Dodick DW. Treatment of medication-overuse headache: a systematic review. Cephalalgia. 2016 Apr;36(4):371-86. doi:10.1177/0333102415593088. Epub 2015 Jun 29.; Rossi P, Di Lorenzo C, Faroni J. Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized trial in transformed migraine patients with low medical needs. Cephalalgia. 2006;26(9):1097-105. doi:10.1111/j.1468-2982.2006.01175.x; Toom K, Braschinsky M, Obermann M, Katsarava Z. Secondary headache attributed to exposure to or overuse of a substance. Cephalalgia. 2021 Apr;41(4):443-52. doi:10.1177/0333102420942238; Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007 Feb;47(2):170-80. doi:10.1111/j.1526-4610.2006.00684.x; Negro A, Curto M, Lionetto L, Martelletti P. A two years open-label prospective study of OnabotulinumtoxinA. 195 U in medication overuse headache: a real-world experience. J Headache Pain. 2015;17:1. doi:10.1186/s10194-016-0591-3. Epub 2016 Jan 21.; Pazdera L, Ning X, Campos VR, et al. Efficacy of fremanezumab in patients with migraine and documented inadequate response to 3 or 4 migraine preventive medication classes and medication overuse in the international, multicenter, randomized placebo-controlled FOCUS study. Poster, 14th European Headache Federation Congress, 2020. doi:10.1186/s10194-021-01232-8; Raggi A, Giovannetti AM, Leonardi M, et al. Predictors of 12-Months Relapse After Withdrawal Treatment in Hospitalized Patients With Chronic Migraine Associated With Medication Overuse: A Longitudinal Observational Study. Headache. 2017 Jan;57(1):60-70. doi:10.1111/head.12979; Zidverc-Trajkovic JJ, Pekmezovic T, Jovanovic Z, et al. Long-term predictors of remission in patients treated for medication-overuse headache at a specialized headache center: A prospective cohort study. Cephalalgia. 2018 Feb;38(2):265-73. doi:10.1177/0333102416683918
-
4Academic Journal
-
5Academic Journal
Authors: Filatova, E. G., Osipova, V. V., Tabeeva, G. R., Parfenov, V. A., Ekusheva, E. V., Azimova, Yu. E., Latysheva, N. V., Naprienko, M. V., Skorobogatykh, K. V., Sergeev, A. V., Golovacheva, V. A., Lebedeva, E. R., Artyomenko, A. R., Kurushina, O. V., Koreshkina, M. I., Amelin, A. V., Akhmadeeva, L. R., Rachin, A. P., Isagulyan, E. D., Danilov, Al. B., Gekht, A. B., Азимова, Ю. Э., Латышева, Н. В., Наприенко, М. В., Скоробогатых, К. В., Сергеев, А. В., Головачева, В. А., Лебедева, Е. Р., Артёменко, А. Р., Курушина, О. В., Корешкина, М. И., Амелин, А. В., Ахмадеева, Л. Р., Рачин, А. П., Исагулян, Э. Д., Данилов, Ал. Б., Гехт, А. Б.
Subject Terms: MIGRAINE, DIAGNOSIS, TREATMENT, CLINICAL GUIDELINES, PREVENTIVE THERAPY, SEIZURE RELIEF THERAPY, NON-DRUG METHODS, МИГРЕНЬ, ДИАГНОСТИКА, ЛЕЧЕНИЕ, КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ, ПРОФИЛАКТИЧЕСКАЯ ТЕРАПИЯ, ТЕРАПИЯ ДЛЯ КУПИРОВАНИЯ, НЕЛЕКАРСТВЕННЫЕ МЕТОДЫ
File Description: application/pdf
Relation: Scopus; http://elib.usma.ru/handle/usma/7181
Availability: http://elib.usma.ru/handle/usma/7181
-
6Academic Journal
Authors: E. G. Filatova, V. V. Osipova, G. R. Tabeeva, V. A. Parfenov, E. V. Ekusheva, Yu. E. Azimova, N. V. Latysheva, M. V. Naprienko, K. V. Skorobogatykh, A. V. Sergeev, V. A. Golovacheva, E. R. Lebedeva, A. R. Artyomenko, O. V. Kurushina, M. I. Koreshkina, A. V. Amelin, L. R. Akhmadeeva, A. R. Rachin, E. D. Isagulyan, Al. B. Danilov, A. B. Gekht, Е. Г. Филатова, В. В. Осипова, Г. Р. Табеева, В. А. Парфенов, Е. В. Екушева, Ю. Э. Азимова, Н. В. Латышева, М. В. Наприенко, К. В. Скоробогатых, А. В. Сергеев, В. А. Головачева, Е. Р. Лебедева, А. Р. Артёменко, О. В. Курушина, М. И. Корешкина, А. В. Амелин, Л. Р. Ахмадеева, А. П. Рачин, Э. Д. Исагулян, Ал. Б. Данилов, А. Б. Гехт
Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 12, No 4 (2020); 4-14 ; Неврология, нейропсихиатрия, психосоматика; Vol 12, No 4 (2020); 4-14 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2020-4
Subject Terms: нелекарственные методы, diagnosis, treatment, clinical guidelines, preventive therapy, seizure relief therapy, non-drug methods, диагностика, лечение, клинические рекомендации, профилактическая терапия, терапия для купирования
File Description: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/1404/1085; Амелин АВ, Игнатов ЮД, Скоромец АА, Соколов АЮ. Мигрень (патогенез, клиника, лечение). Москва: МЕДпресс; 2011. 265 с.; Осипова ВВ, Табеева ГР. Первичные головные боли: диагностика, клиника, терапия: Практическое руководство. Москва: Медицинское информационное агентство; 2014. 336 с.; Табеева ГР, Яхно НН. Мигрень. Москва: ГЭОТАР-Медиа; 2011. 622 с.; Сергеев АВ, Табеева ГР, Азимова ЮЭ. Центральная нейрональная гипервозбудимость – предиспозиция к мигрени. Российский журнал боли. 2010;2(27):3-11.; Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population – a prevalence study. J Clin Epidemiol. 1991;44:1147-57. doi:10.1016/08954356(91)90147-2; Ayzenberg I, Katsarava Z, Sborowski A, et al. The prevalence of primary headache disorders in Russia: A countrywide survey. Cephalalgia. 2012;32(5):373-81. doi:10.1177/0333102412438977; Лебедева ЕР, Кобзева НР, Гилев ДВ, Олесен Ес. Анализ качества диагностики и лечения первичных головных болей в различных социальных группах Уральского региона. Неврология, нейропсихиатрия, психосоматика. 2015;7(1):19-26. doi:10.14412/2074-2711-2015-1-19-26; GBD 2015 Neurological Disorders Collaborator Group Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017 Nov;16(11):877-89.; Яхно НН, Парфенов ВА, Алексеев ВВ. Головная боль (справочное руководство для врачей). Москва: Р-врач; 2000. 150 с.; Парфенов ВА, Головачева ВА. Хроническая боль и ее лечение в неврологии. Москва: ГЭОТАР-Медиа; 2018.; Головачева ВА, Парфенов ВА, Табеева ГР и др. Оптимизация ведения пациентов с хронической ежедневной головной болью. Журнал неврологии и психиатрии им. С.С. Корсакова. 2017;117(2):4-9. doi:10.17116/jnevro2017117214-9; Головачева ВА, Парфенов ВА. Когнитивно-поведенческая терапия в лечении хронической ежедневной головной боли. Анналы клинической и экспериментальной неврологии. 2019;13(3):63-70. doi:10.25692/ACEN.2019.3; Осипова ВВ, Азимова ЮЭ, Табеева ГР и др. Диагностика головных болей в России и странах постсоветского пространства: состояние проблемы и пути ее решения. Анналы клинической и экспериментальной неврологии. 2012;6(2):16-21.; Тарасова СВ, Амелин АВ, Скоромец АА. Распространенность и выявляемость первичных и симптоматических форм хронической ежедневной головной боли. Казанский медицинский журнал. 2008;89(4):427-31.; Kowacs PA, Twardowschy CA, Piovesan EJ, et al. General practice physician knowledge about headache: evaluation of the municipal continual medical education program. Arq Neuro-Psiquiatr. 2009;67:3. doi:10.1590/s0004-282x2009000400004; Cevoli S, D'Amico D, Martelletti P, et al. Underdiagnosis and undertreatment of survey migraine in Italy: a survey of patients attending for the first time 10 headache centers. Cephalalgia. 2009;29:1285-93. doi:10.1111/j.1468-2982.2009.01874.x; The International Classification of Headache Disorders, 3 rd edition (ICHD-3). Cephalalgia. 2018;38(1):1-211. doi:10.1177/0333102417738202; Осипова ВВ. Мигрень и головная боль напряжения. В кн.: Гусев ЕИ, Коновалов АН, редакторы. Клинические рекомендации. Неврология и нейрохирургия. 2-е изд., перераб. и доп. Москва: ГЭОТАР-Медиа; 2015. 424. с.; Lebedeva ER, Gurary NM, Gilev DV, Olesen J. Prospective testing of ICHD-3 beta diagnostic criteria for migraine with aura and migraine with typical aura in patients with transient ischemic attacks. Cephalalgia. 2018;38(3):561-7. doi:10.1177/0333102417702121; Lebedeva ER, Gurary NM, Gilev DV, et al. Explicit diagnostic criteria for transient ischemic attacks to differentiate it from migraine with aura. Cephalalgia. 2018;38(8):1463-70. doi:10.1177/0333102417736901; Екушева ЕВ, Карпова МИ, Осипова ВВ. Гормональные контрацептивы и риск ишемического инсульта у женщин с мигренью: новый международный консенсус. Неврология, нейропсихиатрия и психосоматика. 2019;11(3):11-5. doi:10.14412/2074-2711-2019-3-11-15; Lipton RB, Serrano D, Buse DC, et al. Improving the detection of chronic migraine: Development and validation of Identify Chronic Migraine (ID-CM). Cephalalgia. 2016;36(3):203-15. doi:10.1177/0333102415583982; Артеменко АР, Куренков АЛ, Беломестова КВ. Классификация, диагностика и лечение хронической мигрени: обзор новых данных. Журнал неврологии и психиатрии им. С.С. Корсакова. 2013;(11):91-6.; Zeeberg P, Olesen J, Jensen R. Medication overuse headache and chronic migraine in a specialized headache centre: field-testing proposed new appendix criteria. Cephalalgia. 2009;29(2):214-20. doi:10.1111/j.1468-2982.2008.01710.x; Осипова ВВ, Филатова ЕГ, Артеменко АР и др. Диагностика и лечение мигрени: рекомендации российских экспертов. Журнал неврологии и психиатрии им. Корсакова 2017;(2):28-42.; Steiner TJ, MacGregor EA, Davies PTG. Guidelines for all healthcare professionals in the diagnosis and management of migraine, tension-type, cluster and medication overuse headache. 3 rd ed. British Association for the Study of Headache; 2007.; Reference programme: Diagnosis and treatment of headache disorders and facial pain. Danish Headache Society. 2 nd ed, 2012. J Headache Pain. 2012;13:S1-S29. doi:10.1007/s10194-011-0402-9; Mitsikostas D, Ashina M, Craven A, et al. EHF committee. European Headache Federation Consensus on Technical Investigation for Primary Headache Disorders. J Headache Pain. 2015;17:5. doi:10.1186/s10194-016-0596-y; Academy of Neurology. The utility of neuroimaging in the evaluation of headache in patients with normal neurological examinations. Neurology. 1994;44:1353-4. doi:10.1212/WNL.44.7.1353; Mett A, Tfelt-Hansen P. Acute migraine therapy: recent evidence from randomized comparative trials. Curr Opin Neurol. 2008;21(3):331-7. doi:10.1097/WCO.0b013e3282fee843; Orr SL, Aube M, Becker WJ, et al. Canadian Headache Society systematic review and recommendations on the treatment of migraine pain in emergency settings. Cephalalgia. 2015;35:271. doi:10.1177/0333102414535997; Kirthi V, Derry S, Moore R. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013;4:CD008041. doi:10.1002/14651858.CD008041.pub3; Lampl C, Voelker M, Diener HC. Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. J Neurol. 2007;254(6):705-12. doi:10.1007/s00415-007-0547-2; Suthisisang C, Poolsup N, Kittikulsuth W, et al. Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis. Ann Pharmacother. 2007;41(11):1782-91. doi:10.1345/aph.1K121; Rabbie R, Derry S, Moore RA. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013;4:CD008039. doi:10.1002/14651858.CD008039.pub3; Suthisisang CC, Poolsup N, Suksomboon N, et al. Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine. Headache. 2010;50(5):808-18. doi:10.1111/j.1526-4610.2010.01635.x; Law S, Derry S, Moore RA. Naproxen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013;10:CD009455. doi:10.1002/14651858.CD009455.pub2; Derry S, Rabbie R, Moore RA. Diclofenac with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013;4:CD008783. doi:10.1002/14651858.CD008039.pub3; Derry S, Moore RA. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013;4:CD008040. doi:10.1002/14651858.CD008040.pub3; Diener HC, Montagna P, Gacs G, et al. Efficacy and tolerability of diclofenac potassium sachets in migraine: A randomized, doubleblind, cross-over study in comparison with diclofenac potassium tablets and placebo. Cephalalgia. 2006;26:537-47. doi:10.1111/j.1468-2982.2005.01064.x; Colman I, Brown MD, Innes GD, et al. Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ. 2004;329(7479):1369-73. doi:10.1136/bmj.38281.595718.7C; Shrestha M, Singh R, Moreden J, Hayes JE. Ketorolac vs chlorpromazine in the treatment of acute migraine without aura. A prospective, randomized, double-blind trial. Arch Intern Med. 1996;156:1725-8. doi:10.1001/archinte.1996.00440140163017; Cameron C, Kelly S, Hsieh SC, et al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache. 2015;55(Suppl 4):221-35. doi:10.1111/head.12601; Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22:633-58. doi:10.1046/j.14682982.2002.00404.x; Lipton RB, Bigal ME, Goadsby PJ. Double-blind clinical trials of oral triptans vs other classes of acute migraine medication. A review. Cephalalgia. 2004;24:321-32. doi:10.1111/j.1468-2982.2003.00690.x; Pascual J, Mateos V, Roig C, et al. Marketed oral triptans in the acute treatment of migraine: A systematic review on efficacy and tolerability. Headache. 2007;47:1152-68. doi:10.1111/j.1526-4610.2007.00849.x; Smith LA, Oldman AD, McQuay HJ, Moore RA. Eletriptan for acute migraine. Cochrane Database Syst Rev. 2001:CD003224. doi:10.1002/14651858.CD003224.pub2; Филатова ЕГ, Амелин АВ, Табеева ГР и др. Ready – первое российское мультицентровое исследование эффективности препарата релпакс (элетриптан) при лечении мигрени. Лечение нервных болезней. 2006;(2):19-22.; Bigal ME, Bordini CA, Speciali JG. Intravenous chlorpromazine in the emergency department treatment of migraines: a randomized controlled trial. J Emerg Med. 2002;23(2):141-8. doi:10.1016/S07364679(02)00502-4; Gungor F, Akyol KC, Kesapli M, et al. Intravenous dexketoprofen vs placebo for migraine attack in the emergency department: A randomized, placebo-controlled trial. Cephalalgia. 2016;36:179-84. doi:10.1177/0333102415584604; Duarte C, Dunaway F, Turner L, et al. Ketorolac versus meperidine and hydroxyzine in the treatment of acute migraine headache: A randomized, prospective, double-blind trial. Ann Emerg Med. 1992;21:1116-21. doi:10.1016/S0196-0644(05)80654-7; Bigal ME, Bordini CA, Tepper SJ, et al. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura: A randomized, doubleblind, placebo-controlled study. Cephalalgia. 2002;22:345-53. doi:10.1046/j.14682982.2002.00364.x; Corbo J, Esses D, Bijur PE, et al. Randomized clinical trial of intravenous magnesium sulfate as an adjunctive medication for emergency department treatment of migraine headache. Ann Emerg Med. 2001;38:621-7. doi:10.1067/mem.2001.119424; Cete Y, Dora B, Ertan C, et al. A randomized prospective placebo-controlled study of intravenous magnesium sulphate vs. metoclopramide in the management of acute migraine attacks in the emergency department. Cephalalgia. 2005;25:199-204. doi:10.1111/j.1468-2982.2004.00840.x; Leniger T, Pageler L, Stude P, Diener HC, Limmroth V. Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks. Headache. 2005;45:42-6. doi:10.1111/j.15264610.2005.05009.x; Tanen DA, Miller S, French T, Riffenburgh RH. Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: A prospective, randomized, doubleblind trial. Ann Emerg Med. 2003;41:847-53. doi:10.1067/mem.2003.195; Woldeamanuel YW, Rapoport AM, Cowan RP. The place of corticosteroids in migraine attack management: a 65-year systematic review with pooled analysis and critical appraisal. Cephalalgia. 2015;35(11):996-1024. doi:10.1177/0333102414566200; Friedman BW, Greenwald P, Bania TC, et al. Randomized trial of IV dexamethasone for acute migraine in the emergency department. Neurology. 2007;69:2038-44. doi:10.1212/01.WNL.0000281105.78936.1d; Colman I, Friedman BW, Brown MD, et al. Parenteral dexamethasone for acute severe migraine headache: Meta-analysis of randomised controlled trials for preventing recurrence. BMJ. 2008;336:1359-61. doi:10.1136/bmj.39566.806725.BE; Neill A, Brannigan D. Towards evidencebased emergency medicine: Best BETs from the Manchester Royal Infirmary. BET 2: Dexamethasone for reduction of migraine recurrence. Emerg Med J. 2013;30:165-6. doi:10.1136/emermed-2012-202190.3; Dekker F, Neven AK, Andriesse B, et al. Prophylactic treatment of migraine by GPs: a qualitative study. Br J Gen Pract. 2012;62(597):268-74. doi:10.3399/bjgp12X636100; Jackson JL, Cogbill E, Santana-Davila R, et al. Comparative effectiveness meta-analysis of drugs for the pophylaxis of migraine headache. PLoS One. 2015;10(7):e0130733. doi:10.1371/journal.pone.0130733; He A, Song D, Zhang L, Li C. Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network-meta analysis. J Headache Pain. 2017;18(1):26. doi:10.1186/s10194-017-0720-7; Holroyd KA, Penzien DB, Cordingley GE. Propranolol in the management of recurrent migraine: a meta-analytic review. Headache. 1991;31(5):333-40. doi:10.1111/j.15264610.1991.hed3105333.x; Kangasniemi P, Hedman C. Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A doubleblind study. Cephalalgia. 1984;4:91-6. doi:10.1046/j.1468-2982.1984.0402091.x; Chronicle EP, Mulleners WM. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev. 2016;5:CD003226. doi:10.1002/14651858.CD003226.pub3; Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;6:CD010611. doi:10.1002/14651858.CD010611; Bussone G, Diener HC, Pfeil J, Schwalen S. Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. Int J Clin Pract. 2005;59:961-8. doi:10.1111/j.1368-5031.2005.00612.x; Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial. Headache. 2007;47:170-80. doi:10.1111/j.15264610.2006.00684.x; Herd CP, Tomlinson CL, Rick C, et al. Botulinum toxins for the prevention of migraine in adults. Cochrane Database Syst Rev. 2018;6:CD011616. doi:10.1002/14651858.CD011616.pub2; Dodick DW, Ashina M, Brandes JL, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38:1026-37. doi:10.1177/0333102418759786; Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine a randomized clinical trial. JAMA. 2018;319(19):1999-2008. doi:10.1001/jama.2018.4853; Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab forpreventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:425-34. doi:10.1016/S1474-4422(17)30083-2; Bigal M, Dodick DW, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14:1081-90. doi:10.1016/S1474-4422(15)00249-5; Jackson JL, Shimeall W, Sessums L, et al. Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ. 2010;341:c5222. doi:10.1136/bmj.c5222; Xu XM, Yang C, Liu Y, et al. Efficacy and feasibility of antidepressants for the prevention of migraine in adults: a meta-analysis. Eur J Neurol. 2017;24(8):1022-31. doi:10.1111/ene.13320; Bulut S, Berilgen MS, Baran A, et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg. 2004;107:44-8. doi:10.1016/j.clineuro.2004.03.004; Ozyalcin SN, Talu GK, Kiziltan E, et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache. 2005;45:144-52. doi:10.1111/j.15264610.2005.05029.x; Tronvik E, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003;289:65-9. doi:10.1001/jama.289.1.65; Stovner LJ, Linde M, Gravdahl GB, et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double crossover study. Cephalalgia. 2014;34(7):523-32. doi:10.1177/0333102413515348; Chiang CC, Schwedt TJ, Wang SJ, Dodick DW. Treatment of medication-overuse headache: A systematic review. Cephalalgia. 2016;36:371-86. doi:10.1177/0333102415593088; De Goffau MJ, Klaver ARE, Willemsen MG, et al. The effectiveness of treatments for patients with medication overuse headache: a systematic review and meta-analysis. J Pain. 2017;18(6):615-27. doi:10.1016/j.jpain.2016.12.005; Sandrini G, Perrotta A, Tassorelli C, et al. Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: A multicenter, double-blind, randomized, placebo-controlled, parallel group study. J Headache Pain. 2011;12:427-33. doi:10.1007/s10194-011-0339-z; Silberstein SD, Blumenfeld AM, Cady R, et al. Onabotulinumtoxin A for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci. 2013;331:48-56. doi:10.1016/j.jns.2013.05.003; Kristoffersen ES, Straand J, Vetvik KG, et al. Brief intervention for medication-overuse headache in primary care. The BIMOH study: a double-blind pragmatic cluster randomised parallel controlled trial. J Neurol Neurosurg Psychiatry. 2015;86(5):505-10. doi:10.1136/jnnp-2014-308548; Hagen K, Albretsen C, Vilming ST, et al. Management of medication overuse headache: 1-year randomized multicentre open-label trial. Cephalalgia. 2009;29:221-32. doi:10.1111/j.1468-2982.2008.01711.x; Bottiroli S, Allena M, Sances G, et al; COMOESTAS Consortium. Psychological, clinical, and therapeutic predictors of the outcome of detoxification in a large clinical population of medication-overuse headache: A sixmonth follow-up of the COMOESTAS Project. Cephalalgia. 2018;1:333102418783317. doi:10.1177/0333102418783317; Luedtke K, Allers A, Schulte LH, May A. Efficacy of interventions used by physiotherapists for patients with headache and migraine. Systematic review and meta-analysis. Cephalalgia. 2016;36(5):474-92. doi:10.1177/0333102415597889; Millstine D, Chen CY, Bauer B. Complementary and integrative medicine in the management of headache. BMJ. 2017;16;357:j1805. doi:10.1136/bmj.j1805; Giannitrapani KF, Holliday JR, Miake-Lye IM, et al. Synthesizing the strength of the evidence of complementary and integrative health therapies for pain. Pain Med. 2019;20(9):1831-40. doi:10.1093/pm/pnz068; Andrasik F. What does the evidence show? Efficacy of behavioural treatments for recurrent headache in adults. Neurol Sci. 2007;28:70-7. doi:10.1007/s10072-007-0754-8; Wallasch T-M, Kropp P. Multidisciplinary integrated headache care: a prospective 12-month follow-up observational study. J Headache Pain. 2012;13:521-9. doi:10.1007/s10194-012-0469-y; Gaul C, van Doorn C, Webering N, et al. Clinical outcome of a headache-specific multidisciplinary treatment program and adherence to treatment recommendations in a tertiary headache center: an observational study. J Headache Pain. 2011;12:475-83. doi:10.1007/s10194-011-0348-y; Wallasch TM, Angeli A, Kropp P. Outcomes of headache-specific cross-sectional multidisciplinary treatment program. Headache. 2012;52(7):1094-105. doi:10.1111/j.1526-4610.2012.02189.x; Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16(1):86-92. doi:10.1007/s11916-011-0233-z; Осипова ВВ. Психологические аспекты боли. Неврология, нейропсихиатрия, психосоматика. 2010;2(1):4-8. doi:10.14412/2074-2711-2010-62; Raggi A, Grignani E, Leonardi M, et al. Behavioral Approaches for Primary Headaches: Recent Advances. Headache. 2018;58(6):913-25. doi:10.1111/head.13337; Головачева ВА, Парфенов ВА. Когнитивно-поведенческая терапия в лечении пациентов с мигренью. Неврологический журнал. 2015;3(20):37-43.; Sharpe L, Dudeney J, Williams ACDC, et al. Psychological therapies for the prevention of migraine in adults. Cochrane Database Syst Rev. 2019;7:CD012295. doi:10.1002/14651858.CD012295.pub2; Evers S, Afra J, Frese A, et al; European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine revised report of an EFNS task force. Eur J Neurol. 2009;16:968-81. doi:10.1111/j.1468-1331.2009.02748.x; Harris P, Loveman E, Clegg A, et al. Systematic review of cognitive behavioural therapy for the management of headaches and migraines in adults. Br J Pain. 2015;9(4):213-24. doi:10.1177/2049463715578291; Onur OS, Ertem DH, Karsidag C, et al. An open/pilot trial of cognitive behavioral therapy in Turkish patients with refractory chronic migraine. Cogn Neurodyn. 2019 Apr;13(2):183-9. doi:10.1007/s11571-019-09519-y; Otis JD. Managing chronic pain: a cognitive-behavioral therapy: therapist guide. 1 st ed. New York: Oxford University Press; 2007. 114p.; Lee HJ, Lee JH, Cho EY, et al. Efficacy of psychological treatment for headache disorder: a systematic review and meta-analysis. J Headache Pain. 2019;20(1):17. doi:10.1186/s10194-019-0965-4; Anheyer D, Leach MJ, Klose P, et al. Mindfulness-based stress reduction for treating chronic headache: A systematic review and meta-analysis. Cephalalgia. 2019;39(4):544-55. doi:10.1177/0333102418781795; Nestoriuc Y, Martin A. Efficacy of biofeedback for migraine: a meta-analysis. Pain. 2007;128(1-2):111-27. doi:10.1016/j.pain.2006.09.007; Nestoriuc Y, Martin A, Rief W, Andrasik F. Biofeedback treatment for headache disorders: a comprehensive eficacy review. Appl Psychophysiol Biofeedback. 2008;33:125-40. doi:10.1007/s10484-008-9060-3; Falsiroli Maistrello L, Geri T, Gianola S, et al. Effectiveness of trigger point manual treatment on the frequency, intensity, and duration of attacks in primary headaches: a systematic review and meta-analysis of randomized controlled trials. Front Neurol. 2018;9:254. doi:10.3389/fneur.2018.00254; Xu J, Zhang FQ, Pei J, Ji J. Acupuncture for migraine without aura: a systematic review and meta-analysis. J Integr Med. 2018;16(5):312-21. doi:10.1016/j.joim.2018.06.002; Yin Jiang, Peng Bai, Hao Chen, et al. The effect of acupuncture on the quality of life in patients with migraine: a systematic review and meta-analysis. Front Pharmacol. 2018;9:1190. doi:10.3389/fphar.2018.01190; Feng-Jiao Shen, Jia Xu, Yi-Jun Zhan, et al. Acupuncture for migraine: A systematic review and meta-analysis. World J Acupunct Moxibustion. 2019;29(1):7-14. doi:10.1016/j.wjam.2019.03.004; Lemmens J, de Pauw J, van Soom T, et al. The effect of aerobic exercise on the number of migraine days, duration and pain intensity in migraine: a systematic literature review and meta-analysis. J Headache Pain. 2019;20(1):16. doi:10.1186/s10194-019-0961-8; Kroll LS, Hammarlund CS, Linde M, et al. The effects of aerobic exercise for persons with migraine and co-existing tension-type headache and neck pain. A randomized, controlled, clinical trial. Cephalalgia. 2018;38(12):1805-16. doi:10.1177/0333102417752119; Allen SM, Mookadam F, Cha SS, et al. Greater occipital nerve block for acute treatment of migraine headache: a large retrospective cohort study. J Am Board Fam Med. 2018;1(2):211-8. doi:10.3122/jabfm.2018.02.170188; Cuadrado ML, Aledo-Serrano A, Navarro P, et al. Short-term effects of greater occipital nerve blocks in chronic migraine: a double-blind, randomised, placebo-controlled clinical trial. Cephalalgia. 2017;37:864-72. doi:10.1177/0333102416655159; Misra UK, Kalita J, Bhoi SK. High-rate repetitive transcranial magnetic stimulation in migraine prophylaxis: a randomized, placebocontrolled study. J Neurol. 2013;260(11):2793-801. doi:10.1007/s00415-013-7072-2; Conforto AB, Amaro E Jr, Goncalves AL, et al. Randomized, proof-of-principle clinical trial of active transcranial magnetic stimulation in chronic migraine. Cephalalgia. 2014;34(6):464-72. doi:10.1177/0333102413515340; Schoenen J, Vandersmissen B, Jeangette S, et al. Migraine prevention with a supraorbital transcutaneous stimulator. A-randomized-controlled-trial. Neurology. 2013;80:697-704. doi:10.1212/WNL.0b013e3182825055; Chou D, Yugrakh M, Winegarne D, et al. Acute-migraine-therapy-with-external-trigeminal-neurostimulation-ACME-A-randomized-controlled-trial. Cephalalgia. 2019;39(1):3-14. doi:10.1177/0333102418811573; Cadalso RT Jr, Daugherty J, Holmes C, et al. Efficacy of electrical stimulation of the occipital nerve in intractable primary headache disorders: a systematic review with meta-analyses. J Oral Facial Pain Headache. 2018;32(1):40-52. doi:10.11607/ofph.1784; Yang Y, Song M, Fan Y, Ma K. Occipital nerve stimulation for migraine: a systematic review. Pain Pract. 2016;16(4):509-17. doi:10.1111/papr.12303; Schulman EA, Lake AE 3rd , Goadsby PJ, et al. Defining refractory migraine and refractory chronic migraine: proposed criteria from the Refractory Headache Special Interest Section of the American Headache Society. Headache. 2008;48(6):778-82. doi:10.1111/j.15264610.2008.01132.x
-
7Academic Journal
Contributors: Мерц Фарма, ООО
Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 10, No 4 (2018); 81-87 ; Неврология, нейропсихиатрия, психосоматика; Vol 10, No 4 (2018); 81-87 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2018-4
Subject Terms: когнитивно-моторный тренинг, vascular cognitive impairment, dementia, moderate cognitive impairment, pathogenetic therapy, basic symptomatic therapy, NMDA receptor antagonists, acatinol, acetylcholinesterase inhibitors, non-drug treatments, cognitive and motor training, сосудистые когнитивные нарушения, деменция, умеренные когнитивные нарушения, патогенетическая терапия, базисная симптоматическая терапия, антагонисты NMDA-рецепторов, акатинол, ингибиторы ацетилхолинэстеразы, нелекарственные методы лечения
File Description: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/1001/816; Petersen RC, Stevens JC, Ganguli M, et al. Mild cognitive impairment (an evidence-based review). Neurology. 2001 May 8;56(9):1133-42.; Petersen RC. Mild cognitive impairment as a diagnostic entity. JIntern Med. 2004 Sep;256(3): 183-94.; Парфенов ВА, Захаров ВВ, Преображенская ИС. Когнитивные расстройства. Москва: Ремедиум; 2014. 106 с.; Парфенов ВА, Неверовский ДВ. Ведение пациентов с дисциркуляторной энцефалопатией в амбулаторной практике. Неврология, нейропсихиатрия, психосоматика. 2015; 7(1):37-42. doi:10.14412/2074-2711-2015-1-37-42; Barker WW, Luis CA, Kashuba A, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002 Oct-Dec;16(4):203-12.; Kivipelto M, Helkala EL, Laakso M, et al. Middle life vascular risk factors and Alzheimer’s disease in later life: longitudinal population based study. BMJ. 2001 Jun 16;322(7300):1447-51.; Skoog I, Gustafson D. Clinical trials for primary prevention in dementia. In: Rockwood K, Gauthier S, editors. Dementia therapeutic research. London a New York: Taylor a Francis; 2006. P. 189-212.; Iqbal K, Winblad B, Nishumura T, et al, editors. Alzheimer's disease: biology, diagnosis and therapeutics. J. Willey and sons; 1997. 831 p.; Преображенская ИС. Постинсультные когнитивные расстройства: причины, клинические проявления, лечение. Фарматека. 2013;(9):49-53. [Preobrazhenskaya IS. Poststroke cognitive disorders: causes, clinical manifestations, treatment. Farmateka. 2013;(9):49-53. (In Russ.)].; Barba R, Castro MD, del Mar Morin M, et al. Prestroke dementia. Cerebrovasc Dis. 2001;11(3):216-24.; Hachinski V. Vascular dementia: radical redefinition. In: Carlson LA, Gottfries SG; Winblad B, editors. Vascular dementia: etiology, pathogenesis and clinical aspects. S. Karger; 1994. P. 2-4.; Kawashima R. Mental Exercises for Cognitive Function: Clinical Evidence. J Prev Med Public Health. 2013 Jan;46 Suppl 1:S22-7. doi:10.3961/jpmph.2013.46.S.S22. Epub 2013 Jan 30.; Li X, Li D, Li Q, et al. Hippocampal subfield volumetry in patients with subcortical vascular mild cognitive impairment. Sci Rep. 2016 Feb 15;6:20873. doi:10.1038/srep20873.; O’Brien J, Ames D, Gustafson L, et al, editors. Cerebrovascular disease, cognitive impairment and dementia. Second edition. Martin Dunitz; 2004.; Gorelick PB, Scuteri A, Black SE, et al. Vascular Contributions to cognitive impairment and dementia: A Statement for healthcare Professionals from the American Heart Association / American Stroke Association. Stroke. 2011 Sep;42(9):2672-713. doi:10.1161/ STR.0b013e3182299496. Epub 2011 Jul 21.; Парфенов ВА. Профилактика болезни Альцгеймера. Неврология, нейропсихиатрия, психосоматика. 2011;3(3):8-13.; Fu C, Chute DJ, Farag ES, et al. Comorbidity in dementia: an autopsy study. Arch Pathol Lab Med. 2004 Jan;128(1):32-8.; Hulette CM. Brain banking in the United States. JNeuropathol Exp Neurol. 2003 Jul; 62(7):715-22.; Knopman DS, Parisi JE, Boeve BF, et al. Vascular dementia in a population-based autopsy study. Arch Neurol. 2003 Apr;60(4):569-75.; Baskys A, Hou AC. Vascular dementia: pharmacological treatment approaches and perspectives. Clin Interv Aging. 2007;2(3):327-35.; Kim GH, Lee JH, Seo SW, et al. Hippocampal volume and shape in pure subcortical vascular dementia. Neurobiol Aging. 2015 Jan;36(1):485-91. doi:10.1016/j.neurobiolag-ing.2014.08.009. Epub 2014 Sep 28.; Захаров ВВ. Медикаментозная терапия в восстановительном периоде инсульта. Фар-матека. 2015;(9):80-7.; Butefisch CM. Plasticity in the human cerebral cortex: lessons from the normal brain and from stroke. Neuroscientist. 2004 Apr;10(2):163-73.; L0mo T. The discovery of long-term potentiation. Philos Trans R Soc Lond B Biol Sci. 2003 Apr 29;358(1432):617-20.; Ziemann U, Muellbacher W, Hallett M, Cohen LG. Modulation of practice-dependent plasticity in human motor cortex. Brain. 2001 Jun;124(Pt 6):1171-81.; Захаров ВВ. Глутаматергическая терапия в восстановительном периоде после ишемического инсульта. Эффективная фармакотерапия. Неврология. 2014;(4):6-16.; Thomas SJ, Grossberg GT. Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias. Clin Interv Aging. 2009;4:367-77. Epub 2009 Oct 12.; Areosa Sastre A, Sheriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003154.; Orgogozo JM, Rigaud AS, Sto ffler A, et al. Efficacy and Safety of Memantine in Patients with Mild to Moderate Vascular Dementia a Randomized, Placebo-Controlled Trial (MMM 300). Stroke. 2002 Jul;33(7):1834-9.; Wilcock G, Mo bius HJ, Sto ffler A; MMM 500 group. A double-blind, placebo-controlled multicenter study of Memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002 Nov;17(6):297-305.; Левин ОС, Юнищенко НА, Дударова МА. Эффективность акатинола мемантина при умеренно выраженном когнитивном расстройстве. Журнал неврологии и психиатрии им. С.С. Корсакова. 2009;(7):36-42.; Яхно НН, Преображенская ИС, Захаров ВВ, Мхитарян ЭА. Эффективность мемантина у пациентов с недементными когнитивными расстройствами. Результаты многоцентрового клинического наблюдения. Неврологический журнал. 2010;15(2): 52-8.; Woods B, Aguirre E, Spector AE, Orrell M. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database Syst Rev. 2012 Feb 15;(2):CD005562. doi:10.1002/14651858.CD005562.pub2.; Martin M, Clare L, Altgassen AM, et al. Cognition-based interventions for healthy older people and people with mild cognitive impairment. Cochrane Database Syst Rev. 2011 Jan 19; (1):CD006220. doi:10.1002/14651858.CD006220.pub2.; Young J, Angevaren M, Rusted J, Tabet N. Aerobic exercise to improve cognitive function in older people without known cognitive impairment. Cochrane Database Syst Rev. 2015 Apr 22;(4):CD005381. doi:10.1002/14651858.CD005381.pub4.; Rodakowski J, Saghafi E, Butters MA, Skidmore ER. Non-pharmacological interventions for adults with mild cognitive impairment and early stage dementia: An updated scoping review. Mol Aspects Med. 2015 Jun-Oct; 43-44:38-53. doi:10.1016/j.mam.2015.06.003. Epub 2015 Jun 10.; Науменко АА, Громова ДО, Преображенская ИС. Когнитивный тренинг и реабилитация пациентов с когнитивными нарушениями. Доктор. Ру. 2017;(11):31-8.; Baker LD, Frank LL, Foster-Schubert K, et al. Effects of Aerobic Exercise on Mild Cognitive Impairment: A Controlled Trial. Arch Neurol. 2010 Jan;67(1):71-9. doi:10.1001/arch-neurol.2009.307.; Schmidt W, Endres M, Dimeo F, Jungehulsing GJ. Train the vessel, gain the brain: physical activity and vessel function and the impact on stroke prevention and outcome in cerebrovascular disease. Cerebrovasc Dis. 2013; 35(4):303-12. doi:10.1159/000347061. Epub 2013 Apr 10.; Bherer L. Cognitive plasticity in older adults: effects of cognitive training and physical exercise. Ann N YAcad Sci. 2015 Mar;1337:1-6. doi:10.1111/nyas.12682.; Bherer L, Kramer AF, Peterson MS, et al. Transfer effects in task-set cost and dual-task cost after dual-task training in older and younger adults: further evidence for cognitive plasticity in attentional control in late adulthood. Exp Aging Res. 2008 Jul-Sep;34(3): 188-219. doi:10.1080/03610730802070068.; Kolb B, Gibb R. Principles of neuroplasticity and behavior. In: Stuss D, Winocur G, Robertson I, editors. Cognitive neurorehabilitation: Evidence and Application. New York: Cambridge University Press; 2008. P. 6-21.; Wilson RS, Scherr PA, Schneider JA, et al. Relation of cognitive activity to risk of developing Alzheimer disease. Neurology. 2007 Nov 13; 69(20):1911-20. Epub 2007 Jun 27.; Wada M, Noda Y, Shinagawa S, et al. Effect of Education on Alzheimer’s Disease-Related Neuroimaging Biomarkers in Healthy Controls, and Participants with Mild Cognitive Impairment and Alzheimer’s Disease: A CrossSectional Study. JAlzheimers Dis. 2018;63(2): 861-869. doi:10.3233/JAD-171168.; Bayer-Carter JL, Green PS, Montine TJ, et al. Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment. Arch Neurol. 2011 Jun;68(6):743-52. doi:10.1001/archneurol.2011.125.; Del Parigi A, Panza F, Capurso C, Solfrizzi V. Nutritional factors, cognitive decline, and dementia. Arch Neurol. 2011 Jun; 68(6):743-52. doi:10.1001/archneurol.2011.125.; Morris MC, Evans DA, Tangney CC, et al. Associations of vegetable and fruit consumption with age-related cognitive change. Neurology. 2006 Oct 24;67(8):1370-6.; Rozzini L, Costardi D, Chilovi BV, et al. Efficacy of Cognitive Rehabilitation in Patients with Mild Cognitive Impairment Treated with Cholinesterase Inhibitors. John Wiley & Sons; 2007. P. 356-60.
-
8Academic Journal
Authors: A. A. Naumenko, D. O. Gromova, N. V. Trofimova, I. S. Preobrazhenskaya, А. А. Науменко, Д. О. Громова, Н. В. Трофимова, И. А. Преображенская
Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 8, No 4 (2016); 91-97 ; Неврология, нейропсихиатрия, психосоматика; Vol 8, No 4 (2016); 91-97 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2016-4
Subject Terms: когнитивно-моторный тренинг, cerebral amyloidosis, basic symptomatic treatment, central acetylcholinesterase inhibitors, NMDA receptor blockers, akatinol memantine, gantenerumab, nootropic therapy, cerebrolysin, non-drug exposures, cognitive-motor training, церебральный амилоидоз, базисное симптоматическое лечение, ингибиторы центральной ацетилхолинэстеразы, блокаторы NMDA-рецепторов, акатинол мемантин, гантенерумаб, нооторопная терапия, церебролизин, нелекарственные методы воздействия
File Description: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/680/619; Гаврилова СИ, Федорова ЯБ, Колыхалов ИВ и др. Терапевтический потенциал Церебролизина в превентивной терапии болезни Альцгеймера. Журнал неврологии и психиатрии им. С.С. Корсакова. 2008;(8): 24-9. [Gavrilova SI, Fedorova YaB, Kolykhalov IV, et al. The therapeutic potential of Cerebrolysin in the preventative treatment of Alzheimer's disease. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2008;(8):24-9. (In Russ.)].; Гусев ЕИ, Гехт АБ, Белоусов ЮБ и др. Клинические и фармакоэкономические особенности применения Церебролизина в восстановительном лечении ишемического инсульта. Журнал неврологии и психиатрии им. С.С.Корсакова. 2007;(10):26-33. [Gusev EI, Gekht AB, Belousov YuB i dr. Clinical and pharmacoeconomic peculiarities of application of Cerebrolysin in rehabilitation of ischemic stroke. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2007;(10):26-33. (In Russ.)].; Захаров ВВ, Яхно НН. Нарушения памяти. Москва: ГЭОТАР-Медиа; 2001. 160 с. [Zakharov VV, Yakhno NN. Narusheniya pamyati [Memory impairments]. Moscow: GEOTAR-Media; 2001. 160 p.]; Samadi H, Sultzer D. Solanezumab for Alzheimer's disease. Expert Opin Biol Ther. 2011 Jun;11(6):787-98. doi:10.1517/14712598.2011.578573. Epub 2011 Apr 20.; Яхно НН, Захаров ВВ, Локшина АБ и др. Деменции. Руководство для врачей. 3-е издание. Москва: МЕДпресс-информ; 2011. С. 53-75. [Yakhno NN, Zakharov VV, Lokshina AB, et al. Dementsii. Rukovodstvo dlya vrachei [Dementia. A guide for physicians]. 3rd edition. Moscow: MEDpress-inform; 2011. P. 53-75.]; Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology. 2007 Feb 13;68(7):501-8. Epub 2006 Oct 25.; Парфенов ВА, Захаров ВВ, Преображенская ИС. Когнитивные расстройства. Москва: Ремедиум; 2014. 224 с. [Parfenov VA, Zakharov VV, Preobrazhenskaya IS. Kognitivnye rasstroistva [Cognitive impairments]. Moscow: Remedium; 2014. 224 p.]; Преображенская ИС, Громова ДО. Некоторые аспекты терапии нейродегенеративных деменций. Медицинский совет. 2014;(10):36-42. [Preobrazhenskaya IS, Gromova DO. Some aspects of the therapy of neurodegenerative dementia. Meditsinskii sovet. 2014;(10):36-42. (In Russ.)].; Brickman AM, Siedlecki KL, Stern Y. Cognitive and Brain reserve. In: Depp CA, Jeste DV, editors. Successful Cognitive and Emotional Aging. Arlington: American Psychiatric Publishing, Inc; 2010. P. 157-72.; Erickson KI, Colcombe SJ, Wadhwa R, et al. Training-induced plasticity in older adults: effects of training on hemispheric asymmetry. Neurobiol Aging. 2007 Feb;28(2):272-83. Epub 2006 Feb 9.; Chan D, Fox NC, Scahill RI, et al. Patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease. Ann Neurol. 2001 Apr;49(4):433-42.; Dickerson BC, Goncharova I, SullivanMP, et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging. 2001 Sep-Oct;22(5): 747-54.; Killiany RJ, Hyman BT, Gomez-Isla T, et al. MRImeasures of entorhinal cortex vs hippocampus in preclinical AD. Neurology. 2002 Apr 23;58(8):1188-96.; Scahill RI, Schott JM, Stevens JM, et al. Mapping the evolution of regional atrophy in Alzheimer's disease: Unbiased analysis of fluidregistered serial MRI. Proc Natl Acad Sci USA. 2002 Apr 2;99(7):4703-7.; Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl). 1991;82:239-59.; Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain Imaging in Alzheimer Disease. Cold Spring Harb Perspect Med. 2012 Apr;2(4):a006213. doi:10.1101/cshperspect.a006213.; Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010 Jan;9(1):119-28. doi:10.1016/S1474-4422(09)70299-6.; Whitwell JL. Longitudinal imaging: change and causality. Curr Opin Neurol. 2008 Aug;21(4):410-6. doi:10.1097/WCO.0b013e32830719d4.; Toyn JH, Rowley A, Matsuoka Y, et al. γ-Secretase Pharmacology: What Pharmacology Will Work for Alzheimer's Disease? Int JAlzheimers Dis. 2013;2013:849128. doi:10.1155/2013/849128. Epub 2013 Apr 18.; Kerchner GA, Boxer AL. Bapineuzumab. Expert Opin Biol Ther. 2010 Jul;10(7):1121-30. doi:10.1517/14712598.2010.493872.; Novakovic D, Feligioni M, Scaccianoce S, et al. Profile of gantenerumab and its potential in the treatment of Alzheimer's disease. Drug Des Devel Ther. 2013 Nov 13;7:1359-64. doi:10.2147/DDDT.S53401.eCollection 2013.; Vellas B, Carrillo MC, Sampaio C, et al; EU/US/CTAD Task Force Members. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 2013 Jul;9(4):438-44. doi:10.1016/j.jalz.2013.03.007.; Koenigsknecht-Talboo J, Meyer-Luehmann M, Parsadanian M, et al. Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J Neurosci. 2008 Dec 24;28(52):14156-64. doi:10.1523/JNEUROSCI.4147-08.2008.; Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012 Feb;69(2):198-207. doi:10.1001/archneurol.2011.1538.Epub2011 Oct 10.; Senior K. Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol. 2002 May;1(1):3.; Forman MS, Trojanowski JQ, Lee VM. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med. 2004 Oct;10(10):1055-63.; Qaseem A, Snow V, Cross JT Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008 Mar 4;148(5):370-8.; Oertel W, Ross JS, Eggert K, et al. Rationale for transdermal drug administration in Alzheimer's disease. Neurology. 2007 Jul 24;69(4 Suppl 1):S4-9.; Alvarez XA, Cacabelos R, Laredo M, et al. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol. 2006 Jan;13(1):43-54.; Rockenstein E, Adame A, Mante M, et al. Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin. J Neural Transm (Vienna). 2005 Feb;112(2):269-82. Epub 2004 Jul 7.; Rockenstein E, Torrance M, Mante M, et al. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. J Neurosci Res. 2006 May 15;83(7): 1252-61.; Gauthier S, ProaЦo JV, Jia J, et al. Cerebrolysin in Mild-to-Moderate Alzheimer's Disease: A Meta-Analysis of Randomized Controlled Clinical Trials. Dement Geriatr Cogn Disord. 2015;39(5-6):332-47. doi:10.1159/000377672. Epub 2015 Mar 26.; Wey ZH, He QB, Wang H, et al. Metaanalysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease. J Neural Transm (Vienna). 2007;114(5):629-34. Epub 2007 Feb 23.; Weiner MW. Commentary on «Diagnosis of Alzheimer's disease: two decades of progress.» Central role of technology in the treatment and prevention of Alzheimer's disease. Alzheimers Dement. 2005 Oct;1(2):112-3.; Colcombe S, Kramer AF. Fitness effects on the cognitive function of older adults a meta-analytic study. Psychol Sci. 2003 Mar; 14(2):125-30.; Gates N, Fiatarone Singh MA, Sachdev PS, Valenzuela M. The effect of exercise training on cognitive function in older adults with mild cognitive impairment: a meta-analysis of randomized controlled trials. Am J Geriatr Psychiatry. 2013 Nov;21(11):1086-97. doi:10.1016/j.jagp.2013.02.018. Epub 2013 Jul 3.; Rodakowski J, Saghafi E, Butters MA, Skidmore ER. Non-pharmacological interventions for adults with mild cognitive impairment and early stage dementia: An updated scoping review. Mol Aspects Med. 2015 Jun-Oct;43-44: 38-53. doi:10.1016/j.mam.2015.06.003.Epub 2015 Jun 10.; Kawashima R. Mental Exercises for Cognitive Function: Clinical Evidence. J Prev Med Public Health. 2013 Jan;46 Suppl 1:S22-7. doi:10.3961/jpmph.2013.46.S.S22. Epub 2013 Jan 30.; Rozzini L, Costardi D, Chilovi BV, et al. Efficacy of Cognitive Rehabilitation in Patients with Mild Cognitive Impairment Treated with Cholinesterase Inhibitors. 4th ed. JohnWiley & Sons; 2007. P. 356-60.; Yates LA, Orrell M, Spector A, Orgeta V. Service users' involvement in the development of individual Cognitive Stimulation Therapy (iCST) for dementia: a qualitative study. BMC Geriatr. 2015 Feb 6;15:4. doi:10.1186/s12877-015-0004-5.; Boripuntakul S, Kothan S, Methapatara P, et al. Short-Term Effects of Cognitive Training Program for Individuals with Amnestic Mild Cognitive Impairment: a Pilot Study. 2nd ed. Taylor & Francis; 2012. P. 138-49.; van Paasschen J, Clare L, Yuen KS, et al. Cognitive rehabilitation changesmemory-related brain activity in people with Alzheimer disease. Neurorehabil Neural Repair. 2013 Jun;27(5):448-59. doi:10.1177/1545968312471902. Epub 2013 Jan 31.; Belleville S, Bherer L. Biomarkers of cognitive training effects in aging. Curr Transl Geriatr Exp Gerontol Rep. 2012 Apr 19;1(2): 104-110. Print 2012 Jun.; Baker LD, Frank LL, Foster-Schubert K, et al. Effects of Aerobic Exercise on Mild Cognitive Impairment: A Controlled Trial. Arch Neurol. 2010 Jan;67(1):71-9. doi:10.1001/archneurol.2009.307.; Suzuki T, Shimada H, Makizako H, et al. Effects of multicomponent exercise on cognitive function in older adults with amnesticmild cognitive impairment: a randomized controlled trial. BMC Neurol. 2012 Oct 31;12:128. doi:10.1186/1471-2377-12-128.; Schmidt W1, Endres M, Dimeo F, Jungehulsing GJ. Train the vessel, gain the brain: physical activity and vessel function and the impact on stroke prevention and outcome in cerebrovascular disease. Cerebrovasc Dis. 2013;35(4):303-12. doi:10.1159/000347061. Epub 2013 Apr 10.
-
9Academic Journal
-
10Academic Journal
-
11Academic Journal
-
12Academic Journal
-
13Academic Journal
-
14Academic Journal
Authors: КУДАЕВА Л.М., ХЕГАЙ М.М., ГУРТОВЕНКО И.Ю., БОЛОТОВА О.В.
File Description: text/html
-
15Academic Journal
Authors: Дайникова, Е., Пизова, Наталия
Subject Terms: КОГНИТИВНЫЙ РЕЗЕРВ, КОГНИТИВНЫЕ НАРУШЕНИЯ, ЛЕКАРСТВЕННЫЕ И НЕЛЕКАРСТВЕННЫЕ МЕТОДЫ КОРРЕКЦИИ
File Description: text/html
-
16Academic Journal
Source: Политематический сетевой электронный научный журнал Кубанского государственного аграрного университета.
Subject Terms: 3. Good health, МЕТАБОЛИЧЕСКИЙ СИНДРОМ (МС),КЛИМАКТЕРИЧЕСКИЙ ПЕРИОД,СЕКСУАЛЬНАЯ ДИСФУНКЦИЯ,ИНДЕКС ЖЕНСКОГО СЕКСУАЛЬНОГО ФУНКЦИОНИРОВАНИЯ (ИЖСФ),НЕЛЕКАРСТВЕННЫЕ МЕТОДЫ,METABOLIC SYNDROME (MS),CLIMACTERIC PERIOD,SEXUAL DISFUNCTION,FEMALE SEXUAL FUNCTION INDEX (FSFI),NONMEDICAMENTAL METHODS
File Description: text/html
-
17Academic Journal
Source: Здоровье и образование в XXI веке.
Subject Terms: МЕТАБОЛИЧЕСКИЙ СИНДРОМ,КЛИМАКТЕРИЧЕСКИЙ ПЕРИОД,ДИСБАКТЕРИОЗ КИШЕЧНИКА,METABOLIC SYNDROME (MS),CLIMACTERIC PERIOD,NONMEDICAMENTAL METHODS,INTESTINAL DYSBIOSIS,НЕЛЕКАРСТВЕННЫЕ МЕТОДЫ, 3. Good health
File Description: text/html
-
18Academic Journal
Source: Политематический сетевой электронный научный журнал Кубанского государственного аграрного университета.
Subject Terms: МЕТАБОЛИЧЕСКИЙ СИНДРОМ (МС),КЛИМАКТЕРИЧЕСКИЙ ПЕРИОД,ЖЕЛУДОЧНО-КИШЕЧНЫЙ ТРАКТ,НЕЛЕКАРСТВЕННЫЕ МЕТОДЫ,METABOLIC SYNDROME (MS),CLIMACTERIC PERIOD,DIGESTIVE TRACT,NONMEDICAMENTAL METHODS, 3. Good health
File Description: text/html
-
19Academic Journal
Source: Политематический сетевой электронный научный журнал Кубанского государственного аграрного университета.
Subject Terms: МЕТАБОЛИЧЕСКИЙ СИНДРОМ (МС),КЛИМАКТЕРИЧЕСКИЙ ПЕРИОД,УРОГЕНИТАЛЬНЫЕ РАССТРОЙСТВА,НЕЛЕКАРСТВЕННЫЕ МЕТОДЫ,METABOLIC SYNDROME (MS),CLIMACTERIC PERIOD,UROGENITAL DISORDERS,NON-MEDICAMENT METHODS, 3. Good health
File Description: text/html
-
20Academic Journal
Source: Здоровье и образование в XXI веке.
Subject Terms: МЕТАБОЛИЧЕСКИЙ СИНДРОМ (МС),НЕЛЕКАРСТВЕННЫЕ МЕТОДЫ,КЛИМАКТЕРИЧЕСКИЙ ПЕРИОД,УГЛЕВОДНЫЙ ОБМЕН,ЛИПИДНЫЙ ОБМЕН,METABOLIC SYNDROME (MS),CLIMACTERIC PERIOD,NONMEDICAMENTAL METHODS,CARBOHYDRATE METABOLISM,LIPID METABOLISM, 3. Good health
File Description: text/html